Global Neuropathy Pain Treatment Market 2024-2028

Global Neuropathy Pain Treatment Market 2024-2028

The neuropathy pain treatment market is forecasted to grow by USD 5840.05 mn during 2023-2028, accelerating at a CAGR of 10.96% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the presence of a large patient pool of neuropathy pain, a growing focus on the development of drugs for the treatment of diabetic neuropathy pain, and rising penetration of generic drugs.

Technavio's neuropathy pain treatment market is segmented as below:

By Indication

• Diabetic neuropathy
• Chemotherapy-induced neuropathy pain
• Postherpetic neuralgia
• Others

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the development of topical patches for neuropathy pain treatment changing market dynamics as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years. Also, the growing focus on emerging economies and the association between obesity and endocrine disorders will lead to sizable demand in the market.

The report on the neuropathy pain treatment market covers the following areas:

• Neuropathy pain treatment market sizing
• Neuropathy pain treatment market forecast
• Neuropathy pain treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuropathy pain treatment market vendors that include Abbott Laboratories, Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Neuracle Lifesciences Pvt. Ltd., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., and VistaGen Therapeutics Inc.. Also, the neuropathy pain treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.